Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer
Abstract Background Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the d...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13058-020-01306-6 |
id |
doaj-afb42d75b5ee42f1b156380d241ca612 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Laura A. Baker Holly Holliday Daniel Roden Christoph Krisp Sunny Z. Wu Simon Junankar Aurelien A. Serandour Hisham Mohammed Radhika Nair Geetha Sankaranarayanan Andrew M. K. Law Andrea McFarland Peter T. Simpson Sunil Lakhani Eoin Dodson Christina Selinger Lyndal Anderson Goli Samimi Neville F. Hacker Elgene Lim Christopher J. Ormandy Matthew J. Naylor Kaylene Simpson Iva Nikolic Sandra O’Toole Warren Kaplan Mark J. Cowley Jason S. Carroll Mark Molloy Alexander Swarbrick |
spellingShingle |
Laura A. Baker Holly Holliday Daniel Roden Christoph Krisp Sunny Z. Wu Simon Junankar Aurelien A. Serandour Hisham Mohammed Radhika Nair Geetha Sankaranarayanan Andrew M. K. Law Andrea McFarland Peter T. Simpson Sunil Lakhani Eoin Dodson Christina Selinger Lyndal Anderson Goli Samimi Neville F. Hacker Elgene Lim Christopher J. Ormandy Matthew J. Naylor Kaylene Simpson Iva Nikolic Sandra O’Toole Warren Kaplan Mark J. Cowley Jason S. Carroll Mark Molloy Alexander Swarbrick Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer Breast Cancer Research Breast cancer Transcription factor Helix-loop-helix DNA damage |
author_facet |
Laura A. Baker Holly Holliday Daniel Roden Christoph Krisp Sunny Z. Wu Simon Junankar Aurelien A. Serandour Hisham Mohammed Radhika Nair Geetha Sankaranarayanan Andrew M. K. Law Andrea McFarland Peter T. Simpson Sunil Lakhani Eoin Dodson Christina Selinger Lyndal Anderson Goli Samimi Neville F. Hacker Elgene Lim Christopher J. Ormandy Matthew J. Naylor Kaylene Simpson Iva Nikolic Sandra O’Toole Warren Kaplan Mark J. Cowley Jason S. Carroll Mark Molloy Alexander Swarbrick |
author_sort |
Laura A. Baker |
title |
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer |
title_short |
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer |
title_full |
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer |
title_fullStr |
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer |
title_full_unstemmed |
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer |
title_sort |
proteogenomic analysis of inhibitor of differentiation 4 (id4) in basal-like breast cancer |
publisher |
BMC |
series |
Breast Cancer Research |
issn |
1465-542X |
publishDate |
2020-06-01 |
description |
Abstract Background Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for mammary gland development. ID4 is overexpressed in a subset of BLBC patients, associating with a stem-like poor prognosis phenotype, and is necessary for the growth of cell line models of BLBC through unknown mechanisms. Methods Here, we have defined unique molecular insights into the function of ID4 in BLBC and the related disease high-grade serous ovarian cancer (HGSOC), by combining RIME proteomic analysis, ChIP-seq mapping of genomic binding sites and RNA-seq. Results These studies reveal novel interactions with DNA damage response proteins, in particular, mediator of DNA damage checkpoint protein 1 (MDC1). Through MDC1, ID4 interacts with other DNA repair proteins (γH2AX and BRCA1) at fragile chromatin sites. ID4 does not affect transcription at these sites, instead binding to chromatin following DNA damage. Analysis of clinical samples demonstrates that ID4 is amplified and overexpressed at a higher frequency in BRCA1-mutant BLBC compared with sporadic BLBC, providing genetic evidence for an interaction between ID4 and DNA damage repair deficiency. Conclusions These data link the interactions of ID4 with MDC1 to DNA damage repair in the aetiology of BLBC and HGSOC. |
topic |
Breast cancer Transcription factor Helix-loop-helix DNA damage |
url |
http://link.springer.com/article/10.1186/s13058-020-01306-6 |
work_keys_str_mv |
AT lauraabaker proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT hollyholliday proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT danielroden proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT christophkrisp proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT sunnyzwu proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT simonjunankar proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT aurelienaserandour proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT hishammohammed proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT radhikanair proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT geethasankaranarayanan proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT andrewmklaw proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT andreamcfarland proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT petertsimpson proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT sunillakhani proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT eoindodson proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT christinaselinger proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT lyndalanderson proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT golisamimi proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT nevillefhacker proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT elgenelim proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT christopherjormandy proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT matthewjnaylor proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT kaylenesimpson proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT ivanikolic proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT sandraotoole proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT warrenkaplan proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT markjcowley proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT jasonscarroll proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT markmolloy proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer AT alexanderswarbrick proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer |
_version_ |
1721559055349055488 |
spelling |
doaj-afb42d75b5ee42f1b156380d241ca6122021-04-02T15:47:39ZengBMCBreast Cancer Research1465-542X2020-06-0122111810.1186/s13058-020-01306-6Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancerLaura A. Baker0Holly Holliday1Daniel Roden2Christoph Krisp3Sunny Z. Wu4Simon Junankar5Aurelien A. Serandour6Hisham Mohammed7Radhika Nair8Geetha Sankaranarayanan9Andrew M. K. Law10Andrea McFarland11Peter T. Simpson12Sunil Lakhani13Eoin Dodson14Christina Selinger15Lyndal Anderson16Goli Samimi17Neville F. Hacker18Elgene Lim19Christopher J. Ormandy20Matthew J. Naylor21Kaylene Simpson22Iva Nikolic23Sandra O’Toole24Warren Kaplan25Mark J. Cowley26Jason S. Carroll27Mark Molloy28Alexander Swarbrick29The Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchAustralian Proteome Analysis Facility (APAF), Department of Chemistry and Biomolecular Sciences, Macquarie UniversityThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchCancer Research UK, The University of Cambridge, Li Ka Shing CentreCancer Research UK, The University of Cambridge, Li Ka Shing CentreRajiv Gandhi Centre for BiotechnologyCancer Research UK, The University of Cambridge, Li Ka Shing CentreThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchCentre for Clinical Research, Faculty of Medicine, The University of QueenslandCentre for Clinical Research, Faculty of Medicine, The University of QueenslandThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred HospitalDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred HospitalNational Cancer Institute, National Institutes of HealthSchool of Women’s and Children’s Health, University of New South Wales, and Gynaecological Cancer Centre, Royal Hospital for WomenThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchSchool of Medical Sciences and Bosch Institute, Sydney Medical School, The University of SydneyVictorian Centre for Functional Genomics, Peter MacCallum Cancer CentreVictorian Centre for Functional Genomics, Peter MacCallum Cancer CentreThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchCancer Research UK, The University of Cambridge, Li Ka Shing CentreAustralian Proteome Analysis Facility (APAF), Department of Chemistry and Biomolecular Sciences, Macquarie UniversityThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchAbstract Background Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for mammary gland development. ID4 is overexpressed in a subset of BLBC patients, associating with a stem-like poor prognosis phenotype, and is necessary for the growth of cell line models of BLBC through unknown mechanisms. Methods Here, we have defined unique molecular insights into the function of ID4 in BLBC and the related disease high-grade serous ovarian cancer (HGSOC), by combining RIME proteomic analysis, ChIP-seq mapping of genomic binding sites and RNA-seq. Results These studies reveal novel interactions with DNA damage response proteins, in particular, mediator of DNA damage checkpoint protein 1 (MDC1). Through MDC1, ID4 interacts with other DNA repair proteins (γH2AX and BRCA1) at fragile chromatin sites. ID4 does not affect transcription at these sites, instead binding to chromatin following DNA damage. Analysis of clinical samples demonstrates that ID4 is amplified and overexpressed at a higher frequency in BRCA1-mutant BLBC compared with sporadic BLBC, providing genetic evidence for an interaction between ID4 and DNA damage repair deficiency. Conclusions These data link the interactions of ID4 with MDC1 to DNA damage repair in the aetiology of BLBC and HGSOC.http://link.springer.com/article/10.1186/s13058-020-01306-6Breast cancerTranscription factorHelix-loop-helixDNA damage |